Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 4 · below the Ichimoku cloud · RSI 49 · MACD above its signal
None of the 29 investors followed here reported a position in CLCS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CLCS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 78.0 | 7.9 | -16.7 | 2.2 | -2.2 | -2.8 | 14.4 | -0.0 | -53.9 | 24.4 | +2.0% | ||
| 2025 | -11.4 | -4.8 | 8.4 | -6.5 | -19.7 | 23.8 | 27.9 | 7.9 | 2.4 | -8.3 | -1.3 | 31.6 | +42.9% |
| 2024 | -13.0 | 0.0 | -22.3 | -99.9 | 300.0 | 0.0 | 49900.0 | 12.5 | -33.3 | 133.3 | -14.3 | -41.7 | −23.9% |
| 2023 | -52.9 | -30.0 | 50.0 | -99.9 | 33.3 | 75.0 | 200.0 | 28.6 | 22122.2 | -5.0 | -11.0 | -9.4 | −45.9% |
| 2022 | -3.9 | -22.8 | -29.5 | 10.4 | 1.4 | -20.0 | 25.0 | -99.7 | 0.0 | 0.0 | 108.3 | 16900.0 | −33.6% |
| 2021 | -2.5 | -10.3 | -21.1 | -7.2 | 24.2 | 22.6 | 0.0 | -21.2 | -18.0 | 5.5 | 17.3 | -17.9 | −36.0% |
| 2020 | -40.0 | 6.0 | -28.6 | 2.0 | 56.9 | 7.5 | 81.4 | -32.7 | 13.3 | -20.2 | 0.0 | 110.5 | +81.8% |
| 2019 | 6.7 | -31.2 | 30.9 | -9.7 | 5.8 | -17.0 | -3.7 | 36.5 | 2.5 | -7.8 | 25.4 | 23.6 | +46.7% |
| 2018 | 14.8 | 12.9 | 17.1 | 24.4 | 56.9 | 5.0 | -9.5 | -9.2 | 1.4 | 7.1 | -9.3 | 10.3 | +177.8% |
| 2017 | -4.4 | -7.0 | 0.0 | 12.5 | -44.4 | 60.0 | -12.5 | 0.0 | -5.7 | 15.2 | -7.9 | -22.9 | −40.0% |
| 2016 | -12.0 | -9.1 | 0.0 | 5.0 | -23.8 | 18.7 | -5.3 | 66.7 | -26.7 | -31.8 | -33.5 | -9.8 | −64.0% |
| 2015 | -21.8 | 144.2 | 14.3 | 19.2 | -9.1 | -4.6 | -3.2 | -16.7 | 14.0 | 9.6 | 20.0 | -16.7 | +127.3% |
| 2014 | 0.0 | 54.3 | -7.4 | -28.0 | -5.6 | -11.8 | -26.7 | −37.1% |
No insider transactions reported for CLCS.
No analyst coverage for this instrument.
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
No recent headlines.